Atara biotherapeutics reports inducement grant under nasdaq listing rule 5635(c)(4)

Thousand oaks, calif.--( business wire )--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of inducement awards to ricardo fonseca, its new vice president, operations.
ATRA Ratings Summary
ATRA Quant Ranking